MedellinIVF.coMedellín IVFColombian IVFColombia MedicalCompare a quote
Independent fertility planning · Updated October 2026

Repeated Failed Embryo Transfers: What the 2026 ASRM Guidance Changes

ASRM’s 2026 committee opinion redefines recurrent implantation failure, backs a focused evaluation and says many popular tests and treatments lack evidence. Here is what it means for your next step.

Educational information for patients comparing fertility care in Medellín. Not medical advice.

Bottom line: ASRM’s 2026 committee opinion defines recurrent implantation failure (RIF) by probability rather than a fixed count of failures. It recommends a careful review of what can actually be corrected, and it finds many popular tests and treatments either unsupported or not recommended. If nothing correctable turns up, it says further transfers are a reasonable path.

Why a new definition matters

For years “recurrent implantation failure” has meant different things at different clinics. It might mean two failed transfers or five, tested embryos or untested ones. That vagueness matters because the label often unlocks a list of extra tests and treatments.

The ASRM committee opinion on recurrent implantation failure (Fertility and Sterility, 2026) starts by acknowledging that there is no uniform definition. It proposes one based on success probability instead. RIF is the failure to implant after transferring the estimated number of good-quality blastocysts that would normally give a 95% cumulative chance of a positive pregnancy test. Based on current literature, it suggests that is roughly 3 to 6 failed transfers of euploid (chromosomally tested) embryos, or an age-dependent number of untested embryos.

Two details are worth knowing. The opinion uses a positive pregnancy blood test (hCG) as the marker of implantation. It also keeps RIF separate from recurrent pregnancy loss, which requires two pregnancy losses. If you have had positive tests followed by losses, that is a different evaluation.

What the evaluation should include

The core recommendation is to go back through your medical and reproductive history, imaging and the details of each IVF cycle to look for factors that can be corrected. The opinion then addresses specific areas:

Tests and treatments the opinion does not support

This is the section most likely to change what you are offered. The table summarises the opinion’s conclusions.

Test or treatmentASRM 2026 conclusion
Endometrial receptivity analysis (ERA)Insufficient evidence for routine use. Two randomised trials did not show higher live birth rates, and one analysis found poor predictive accuracy.
BCL-6 testingRoutine testing not recommended
Endometrial scratchNot effective and not recommended, given a large 2019 trial showing no benefit
Thrombophilia or antiphospholipid testing, routine heparinInsufficient data to support routine use
Intralipid (fat emulsion) infusionsInsufficient evidence
IVIGNot recommended
G-CSFInsufficient evidence
EtanerceptInsufficient evidence; randomised trials needed
Intrauterine hCG infusionConflicting results; randomised trials needed
Intrauterine PRPInsufficient evidence; most studies lack controls
Sperm DNA fragmentation testingInsufficient evidence for RIF
A specific progesterone regimen for RIFInsufficient data to recommend one

“Insufficient evidence” does not mean proven harmful. It means the treatment has not been shown to help, so paying for it, and sometimes delaying another transfer for it, is a bet rather than standard care. If a clinic recommends one of these, ask why it thinks your case is the exception and whether it would offer the treatment within a research study.

If nothing correctable is found

This may be the most reassuring part of the opinion. If a careful review turns up no correctable cause, the committee says extensive further testing is unnecessary and further transfers are reasonable, because many patients eventually conceive. It also recommends offering social support after failed transfers, and says a gestational carrier can be considered after several failures.

That framing is a useful antidote to the feeling that something must be done differently every time. Sometimes the evidence-based next step is another well-run transfer of a good embryo.

What the opinion does not settle

The committee is open about the limits of the evidence. Much of the research on RIF used different definitions, small numbers of patients or no control group, which is one reason so many treatments end up as “insufficient evidence”. The opinion concludes that high-quality prospective studies using one agreed definition are needed. For you, that means two things. A clinic that is honest about uncertainty is not being unhelpful. And if you are offered an experimental treatment, asking whether it is being given within a properly designed study is a reasonable question, not an awkward one.

It also means emotional support is part of the plan, not an extra. Repeated failed transfers are draining, and the opinion specifically recommends offering social support. If your clinic does not provide counselling, ask your doctor at home for a referral before your next attempt.

Taking a history of failed transfers to a Medellín clinic

If you are considering a Medellín clinic after failures elsewhere, the opinion gives you a frame for judging the consultation.

Prepare a transfer-by-transfer summary

List each transfer with its date, the embryo’s stage and grade, whether it was tested, the type of cycle, the lining measurement if known, any difficulty during the procedure and the pregnancy test result. That table is what a doctor needs to judge whether you meet the probability-based definition at all. Our guide to getting a second opinion after a failed cycle covers the wider record set.

Judge the proposed plan

A plan in line with the 2026 opinion will usually start by reviewing what has already been done. It may suggest repeating a cavity assessment, considering karyotyping, and looking at transfer technique and any endometriosis. A plan that opens with a bundle of immune treatments, receptivity testing and endometrial scratching, without discussing the evidence, deserves careful questions. Our guide to IVF add-ons in a Medellín quote explains how to ask for that evidence.

Think about embryo testing carefully

If your earlier embryos were untested, a clinic may suggest PGT-A next time. ASRM’s 2024 PGT-A opinion and the 2026 RIF opinion both stop short of saying it improves live birth rates. It can help you understand what happened, and it will reduce the number of embryos available. Decide with your doctor whether that information is worth the trade-off.

Questions worth taking to the consultation

  • Do I meet the 2026 ASRM definition, given my age and the embryos transferred?
  • What correctable factors have you found in my history, imaging or cycle records?
  • Should my uterine cavity be reassessed, and by which method?
  • Is karyotyping for my partner and me worth considering?
  • For any add-on you recommend, what does the 2026 opinion say about it, and why is my case different?
  • If nothing correctable is found, what would my next transfer look like?

Already have a fertility treatment quote?

Compare the scope before comparing the sticker price. If you are gathering written estimates, keep the medication, laboratory, freezing, transfer and follow-up lines separate.

Compare a medical quoteExplore Colombia medical care

Considering fertility care in Medellín?

Use the private planning request to describe what you are comparing, your approximate timing and travel readiness. Do not upload medical records; a provider can move clinical information into its secure intake.

Request a fertility introductionCompare written quotes

Frequently asked questions

How many failed transfers count as recurrent implantation failure?

There is no single agreed number. ASRM’s 2026 opinion ties the definition to the number of good-quality blastocysts that would normally give a 95% cumulative chance of a positive pregnancy test. In practice it suggests that is roughly 3 to 6 failed transfers of chromosomally tested embryos, or an age-dependent number of untested ones.

Should I have an endometrial receptivity test after failed transfers?

ASRM’s 2026 opinion finds the evidence insufficient to recommend it routinely. It notes that two randomised trials did not show higher live birth rates and that one analysis found the test predicted outcomes poorly. Ask any clinic recommending it what it expects the result to change.

Do immune treatments like intralipids or IVIG help after failed IVF transfers?

The 2026 opinion says the evidence is insufficient for intralipids and G-CSF and does not recommend IVIG. It reaches similar conclusions about several other immune or intrauterine treatments. These should not be presented as standard care for repeated implantation failure.

Is it reasonable to keep transferring if no cause is found?

Yes, according to ASRM. If a careful review finds nothing correctable, the 2026 opinion says extensive testing is unnecessary and further transfers are reasonable, because many patients eventually conceive.

Would PGT-A help after several failed transfers?

The opinion says PGT-A may be offered for untested embryos through shared decision-making, but that there is no evidence it increases the chance of live birth in this group. Discuss what you would gain and lose before adding it.

Is a gestational carrier ever recommended after failed transfers?

ASRM’s 2026 opinion says a gestational carrier can be considered after several failed transfers. It is a significant personal, legal and financial decision, and it usually comes after the other evaluation steps.

Medical disclaimer: MedellinIVF.co is an independent educational and lead-navigation site, not a fertility clinic. Nothing on this page is diagnosis, treatment advice or a guarantee of outcome. Prices and policies change. Verify current information directly with the treating clinic and appropriate Colombian registries.

Continue researching:MedellinIVF.coColombianIVF.comColombiaMedical.coGetMedicalQuotes.com